GlassScriptPhysician profile
Marcy Carpenter Bryan
NPI 1427641745
$1,282.32
in general payments reported to CMS, 2019-2025
15 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $816 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $839 · Education: $443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $839.34 |
| Education | $442.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $322.42 | 2024-2025 | Jakafi, Niktimvo, Pemazyre |
| Janssen Biotech, INC. | $260.50 | 2024-2025 | Talvey, Darzalex |
| Lilly USA, LLC | $125.01 | 2024 | Verzenio |
| Gilead Sciences, INC. | $112.32 | 2025 | Trodelvy |
| Genentech, INC. | $102.72 | 2024 | Alecensa |
| Aveo Pharmaceuticals, INC. | $99.00 | 2024 | |
| Daiichi Sankyo INC. | $74.99 | 2024 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $54.11 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $23.86 | 2024 | Panhematin |
| Jazz Pharmaceuticals INC. | $22.47 | 2025 | |
| Pharmacosmos Therapeutics INC. | $19.62 | 2025 | Monoferric |
| Glaxosmithkline, LLC. | $18.77 | 2024 | Ojjaara |
| Pfizer INC. | $16.86 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $15.51 | 2025 | |
| Array Biopharma INC | $14.16 | 2024 | Mektovi, Braftovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcy Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.